Cornell makes cancer vaccine for clinical use
Thursday, August 20, 2009 - 18:21
in Health & Medicine
The Bioproduction Facility at Cornell University has produced the first batch of NY-ESO-1 recombinant protein -a cancer vaccine -that will be used in clinical trials for patients facing either ovarian cancer or melanoma. The facility was developed as a partnership between The Ludwig Institute for Cancer Research and Cornell University.
